No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma

Phase 1b/2 study (multi-centre, single-arm)

byKathleen Lau

December 2, 2021

in StudyGraphics

Reading Time: 1 min read

High-titre convalescent plasma therapy not effective against severe COVID-19 pneumonia

RelatedReports

Adalimumab aids in control of noninfectious uveitis

Chronic Disease

Younger age and systemic metastases may independently predict survival among patients with choroidal metastases

August 3, 2026

Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Chronic Disease

A digital mental health intervention may improve anxiety in breast cancer survivors

July 31, 2026

Radiation plus hormone therapy may improve prostate cancer survival

Chronic Disease

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

July 22, 2026

Rectal indomethacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients

Chronic Disease

Chemotherapy exposure is independently associated with reduced pain severity in advanced pancreatic cancer

July 15, 2026

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma

Surgical site anesthetic infusion may enhance analgesia after mastectomy

Peripherally inserted central catheters are associated with twice as many complications than midline catheters when used short-term

AAP recommends focus on nutrient-rich foods in schools

Smartphone-based intervention reduced body mass index and obesity in school children

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma

Phase 1b/2 study (multi-centre, single-arm)

RELATED REPORTS

High-titre convalescent plasma therapy not effective against severe COVID-19 pneumonia

Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma

RelatedReports

Recent Reports